2 mL blood sample
A small blood sample is enough to complete the test.
Circulating Tumor Cell (CTC) Automated detection systems and services
A 3-minute blood draw provides reference information for multi-cancer risk assessment and follow-up.
Good Future specializes in circulating tumor cell (CTC) testing. Using a 2 mL blood sample, the service combines a negative selection workflow, cell-image evidence, and structured reporting. Normal blood cells are removed first so more potential CTC phenotypes can be retained for review and follow-up discussion.
5 business days
Reports are typically delivered within 5 business days.
50+ partner institutions
Trusted by medical institutions, laboratories, and biotech partners.
First dedicated CTC laboratory in Taiwan with ISO certification
Supports trust in laboratory quality, certification, and service consistency.
Key Differentiators
What makes Good Future different
Understand the service features that distinguish Good Future’s CTC testing approach.
Differentiator 01
Negative selection workflow
Removes normal blood cells first and preserves more clinically meaningful CTC phenotypes.
Differentiator 02
Epithelial + mesenchymal testing
Supports review of both epithelial and mesenchymal phenotypes instead of relying on a single signal.
Differentiator 03
Image-supported reporting
Reports include image evidence and interpretation details alongside summary results.
Differentiator 04
Support for follow-up use
Designed to support longitudinal follow-up, molecular testing, and research applications.
Who Is This Test For
Who may benefit from CTC testing?
CTC testing may be considered based on risk profile, suspicious findings, or follow-up needs.
Individuals with higher cancer risk
Family history of cancer
Frequent smoking or drinking
People with concerning health findings
Abnormal imaging findings
Abnormal blood tumor markers
Cancer patients
Monitor treatment response
Monitor risk of recurrence
Partnerships and Milestones
Partnerships and Milestones
From technology licensing and system development to clinical, insurance, and overseas collaboration, Good Future continues to expand where CTC testing can be applied.
Chang Gung Technology License
Inventec Appliances / Inventec
Taipei Veterans General Hospital
Global Life
Nanshan Life Insurance
Chang Gung technology licensing and system development
The Chang Gung technology license became the starting point for R&D and later expanded into automated system development, workflow integration, and service deployment.
Taipei Veterans General Hospital collaboration experience
Collaboration with Taipei Veterans General Hospital helped align the system and service workflow with medical-center practice and strengthen clinical understanding of sampling and image review.
Won the 17th National Innovation Award
The 17th National Innovation Award provided external recognition and strengthened trust in the R&D progress behind Good Future’s automated detection system.
Global Life and Nan Shan Life cooperation
Partnerships with Global Life and Nan Shan Life extended CTC testing from medical settings into corporate and insurance-related service scenarios.
WellSpring Overseas Cooperation Project
Good Future is working with Malaysian smart-health company WellSpring on new projects covering CTC testing, intestinal wellness, and probiotics.
Malaysia regulatory milestone
The CTC detection system obtained a Malaysian medical device license in August 2025, creating a clearer foundation for subsequent market rollout and service implementation.
More Entry Points
More Services and Resources
In addition to testing services, you can quickly reach blood collection, product, and wellness information from the sections below.
Blood Collection Sites
Search by city and district to find blood collection partners and site information.
Products
Browse testing systems, consumables, and related product information.
Health Products
Browse products designed for everyday wellness support.
Featured Resources
Featured news and resources
Quickly review brand updates, technical insights, and video content.
Good Future and Chung Shan Medical University Hospital publish breast cancer CTC study in MDPI Diseases
Quickly review Good Future’s latest published breast cancer CTC study and its core findings.
Circulating Tumor Cell Detection Principle
Start from the testing principle to understand the value of negative selection and cell-image reporting.
Good Future Knowledge Series | CTC overview
Start with a short video overview, then continue to the full resource library for more articles and videos.